2015-09-23
Ark's Anti-RSV AK0529 Successfully Completes Phase 1 Study
SHANGHAI, CHINA- Ark Biosciences, a biotech company developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, today announced the successful completion of phase 1 clinical study of its anti-respi...
know more >
2015-08-04
Ark Completes Series A Financing and Reports Significant Progress for AK0529
SHANGHAI, CHINA- Ark Biosciences, a biotech company developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, announced today successful completion of a Series A financing, led by Qiming Venture ...
know more >